Table 2.
Comparison of recipient characteristics of the 2 subgroups.
| Parameter | All subjects | Donor age ≥50 | Donor age <50 | p value |
|---|---|---|---|---|
| Sex (M/F) | 25/16 | 11/3 | 14/13 | 0.096 |
| Age (years) | 39.2±10.1 | 44.9±10.7 | 36.3±8.6 | 0.008 |
| BMI (kg/m2) | 21.4 (19.1–23.7) | 22.5 (19.9–23.9) | 20.0 (17.9–22.8) | 0.226 |
| Dialysis duration (months) | 12.0 (5.5–51.5) | 11.5 (5.8–29.5) | 16.0 (5.0–63.0) | 0.441 |
| CIT (minutes) | 617.2±228.8 | 556.6±188.1 | 648.7±244.6 | 0.226 |
| HLA mismatch (A, B, DR) | 64.0 (3.0–5.0) | 4.0 (3.0–4.0) | 4.0 (3.0–5.0) | 0.639 |
| DGF, n (%) | 3 (7.3) | 3 (21.4) | 0 (0) | 0.034 |
| Rejection, n (%) | 6 (14.6) | 2 (14.3) | 4 (14.8) | 0.964 |
| Immunosuppressant | 0.355 | |||
| Cyclosporin, n (%) | 11 (26.8) | 5 (35.7) | 6 (22.2) | – |
| Tacrolimus, n (%) | 30 (73.2) | 9 (64.3) | 21 (77.8) | – |
| M1 | ||||
| Serum creatinine (umol/L) | 120.0 (94.5–156.5) | 149.0 (120.8–203.8) | 110.0 (81.0–133.0) | 0.000 |
| eGFR (ml/min/1.73 m2) | 56.0±18.1 | 44.2±15.5 | 62.1±16.5 | 0.002 |
| Serum calcium (mmol/L) | 2.4 (2.3–2.5) | 2.3 (2.3–2.5) | 2.4 (2.3–2.6) | 0.141 |
| Serum phosphate (mmol/L) | 1.1 (0.9–1.3) | 1.2 (1.0–1.8) | 1.0 (0.9–1.3) | 0.102 |
| Serum UA (umol/L) | 387.3±85.4 | 403.7±101.5 | 378.7±76.5 | 0.381 |
| Serum Klotho (pg/ml) | 379.4±135.4 | 343.3±138.6 | 398.1±132.4 | 0.223 |
| Serum FGF-23 (pg/ml) | 593.4 (172.5–2401.9) | 541.5 (172.6–3478.6) | 593.4 (165.3–1620.7) | 0.805 |
| Urinary NGAL (ng/ml) | 6.9 (2.1–13.3) | 12.2 (2.1–19.4) | 4.6 (2.0–11.3) | 0.178 |
| M3 | ||||
| Serum creatinine (umol/L) | 121.0 (95.5–142.5) | 193.0 (121.3–188.5) | 99.0 (84.0–140.0) | 0.004 |
| eGFR (ml/min/1.73 m2) | 61.3±21.4 | 50.6±17.5 | 66.9±21.5 | 0.019 |
| Serum calcium (mmol/L) | 2.5±0.1 | 2.5±0.2 | 2.5±0.1 | 0.738 |
| Serum phosphate (mmol/L) | 1.2±0.3 | 1.3±0.3 | 1.2±0.3 | 0.206 |
| Serum UA (umol/L) | 401.5±109.5 | 409.7±116.0 | 397.2±108.0 | 0.733 |
| Serum Klotho (pg/ml) | 542.1 (370.3–731.5) | 444.9 (329.9–611.8) | 621.7 (423.9–872.9) | 0.054 |
| Serum FGF-23 (pg/ml) | 325.1 (134.6–901.0) | 280.6 (113.8–1804.4) | 357.8 (140.8–771.6) | 0.934 |
| Urinary NGAL (ng/ml) | 5.8 (2.2–14.0) | 8.8 (2.2–24.3) | 4.4 (2.1–10.5) | 0.458 |
| Y1 | ||||
| Serum creatinine (umol/L) | 130.0 (91.5–153.5) | 122.0 (90.8–168.8) | 133.0 (93.0–164.0) | 0.536 |
| eGFR (ml/min/1.73 m2) | 57.7±25.7 | 59.0±25.9 | 57.0±26.0 | 0.822 |
| Serum calcium (mmol/L) | 2.4±0.1 | 2.4±0.1 | 2.4±0.2 | 0.932 |
| Serum phosphate (mmol/L) | 1.2 (1.0–1.3) | 1.2 (1.1–1.4) | 1.2 (1.0–1.2) | 0.156 |
| Serum UA (umol/L) | 405.6±110.1 | 407.3±99.1 | 404.7±117.2 | 0.944 |
| Serum Klotho (pg/ml) | 594.6 (417.4–860.0) | 525.7 (423.4–903.7) | 594.6 (415.6–863.7) | 0.869 |
| Serum FGF-23 (pg/ml) | 103.2 (56.8–169.3) | 152.1 (87.3–293.5) | 73.8 (48.6–148.7) | 0.061 |
| Urinary NGAL (ng/ml) | 8.6 (3.6–22.2) | 6.2 (3.0–49.3) | 8.6 (3.6–14.1) | 0.912 |
BMI – body mass index; CIT – cold ischemia time; DGF – delayed graft function; eGFR – estimated glomerular filtration rate; FGF-23 – fibroblast growth factor-23; HLA – human leucocyte antigen; NGAL – neutrophil gelatinase-associated lipocalin; UA – uric acid.